Literature DB >> 26337328

Healthy adult vaccination: An urgent need to prevent hepatitis B in China.

Yan Qiu1, Jingjing Ren1, Jun Yao2.   

Abstract

Prevalence of hepatitis B is still high among adults in China, athough the prevalence in children has decreased dramatically. Immunization against hepatitis B among adults is urgently required. Through analyzing the immunogenicity of different doses, schedules and booster immunization among adults, we recommend 10 or 20 μg with a 0-1-6-month schedule or a 0-1-12-month schedule for migrant adults. For immunity failure, increasing the dose or covalent vaccine is suggested to provide protective antibodies. To enhance immunity among adults, hepatitis B vaccine should be included in health insurance.

Entities:  

Keywords:  China; healthy adults; hepatitis B; immunization; prevalence

Mesh：

Substances：

Year:  2016        PMID： 26337328      PMCID： PMC4964707          DOI： 10.1080/21645515.2015.1086519

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  15 in total

1.  Analysis of T-cell receptor beta chain variable gene segment usage in healthy adult responders and nonresponders to recombinant hepatitis B vaccine.

Authors:  P Soroosh; F Shokri; M Azizi; M Jeddi-Tehrani
Journal:  Scand J Immunol       Date:  2003-05       Impact factor: 3.487

2.  Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults.

Authors:  Scott A Halperin; Shelly McNeil; Joanne M Langley; Bruce Smith; Donna MacKinnon-Cameron; Robyn McCall-Sani; William L Heyward; J Tyler Martin
Journal:  Vaccine       Date:  2012-06-13       Impact factor: 3.641

3.  Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.

Authors:  Scott A Halperin; Simon Dobson; Shelly McNeil; Joanne M Langley; Bruce Smith; Robyn McCall-Sani; Dan Levitt; Gary Van Nest; Daniel Gennevois; Joseph J Eiden
Journal:  Vaccine       Date:  2005-09-12       Impact factor: 3.641

4.  Comparison of the effect of two different doses of recombinant hepatitis B vaccine on immunogenicity in healthy adults.

Authors:  Jing Li; Jun Yao; Huan Shan; Yongdi Chen; Zheng-gang Jiang; Jing-jing Ren; Kai-jin Xu; Bing Ruan; Shi-gui Yang; Bing Wang; Tian-sheng Xie; Qian Li
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  The response of hepatitis B vaccination on seronegative adults with different vaccination schedules.

Authors:  Jun Yao; Jing Li; Yongdi Chen; Huan Shan; Xue-wei Dai; Lin-na Yang; Zheng-gang Jiang; Jing-jing Ren; Kai-jin Xu; Bing Ruan; Shi-gui Yang; Bing Wang; Tian-sheng Xie; Qian Li
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Effect of revaccination using different schemes among adults with low or undetectable anti-HBs titers after hepatitis B virus vaccination.

Authors:  Chao-Shuang Lin; Shi-Bin Xie; Jing Liu; Zhi-Xin Zhao; Yu-Tian Chong; Zhi-Liang Gao
Journal:  Clin Vaccine Immunol       Date:  2010-08-18

7.  HLA-DRB1, DQA1 and DQB1 alleles and haplotypes frequencies in Iranian healthy adult responders and non-responders to recombinant hepatitis B vaccine.

Authors:  Ali Akbar Amirzargar; Nilufar Mohseni; Mohammad Ali Shokrgozar; Zohreh Arjang; Nahid Ahmadi; Manijeh Yousefi Behzadi; Amir Amanzadeh; Fazel Shokri
Journal:  Iran J Immunol       Date:  2008-06       Impact factor: 1.603

8.  High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees.

Authors:  Angelique P A Vermeiren; Christian J P A Hoebe; Nicole H T M Dukers-Muijrers
Journal:  J Clin Virol       Date:  2013-07-26       Impact factor: 3.168

9.  [Immunoreaction levels of revaccination in healthy population with hepatitis B vaccine].

Authors:  Jian-Qiong Zhu; Zhen-Yu Huang; Dong-Bo Mao
Journal:  Zhongguo Yi Miao He Mian Yi       Date:  2009-04

10.  Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults.

Authors:  Hong-Xing Pan; Ying Zeng; Xue-Fang Song; Yi-Ju Zhang; Ke Xu; Zheng-Lun Liang; Feng-Cai Zhu
Journal:  Vaccine       Date:  2014-03-27       Impact factor: 3.641
View more
  11 in total

1.  Strategies for hepatitis B booster vaccination among children: an 8-year prospective cohort study.

Authors:  Yan Qiu; Jing-Jing Ren; Zi-Kang Wu; Ling-Zhi Shen; Huan Shan; Xue-Wei Dai; Jing Li; Ying Liu; Wen Ren; Jun Yao; Lan-Juan Li
Journal:  Hum Vaccin Immunother       Date:  2020-05-19       Impact factor: 3.452

Review 2.  Influences of obesity on the immunogenicity of Hepatitis B vaccine.

Authors:  Fang Liu; Zhirong Guo; Chen Dong
Journal:  Hum Vaccin Immunother       Date:  2017-01-06       Impact factor: 3.452

3.  The effect of hepatitis B vaccination after five years on an entire population in an insular region of Southeast China.

Authors:  Ying Liu; Jingjing Ren; Zikang Wu; Lingzhi Shen; Huan Shan; Xuewei Dai; Jing Li; Yan Qiu; Wen Ren; Jun Yao; Lanjuan Li
Journal:  Hum Vaccin Immunother       Date:  2020-12-14       Impact factor: 3.452

4.  Hepatitis B virus serological screen in a general hospital in Beijing from 2008 to 2018, and challenges to our vaccination policy.

Authors:  Shaoxia Xu; Weihong Zhang; Qiaofeng Wang; Jingtao Cui; Wenjuan Yan; Hongjie Xie; Anping Ni
Journal:  Vaccine X       Date:  2020-02-14

5.  ALT Flare Predicts Hepatocellular Carcinoma Among Antiviral Treated Patients With Chronic Hepatitis B: A Cross-Country Cohort Study.

Authors:  Yanan Du; Bingying Du; Xiaoyan Fang; Meng Shu; Yongjing Zhang; Hsingwen Chung; Ye Sun; Jiaming Teng; Phimphone Visalath; Hong Qiu; Wei Cai
Journal:  Front Oncol       Date:  2021-01-21       Impact factor: 6.244

6.  12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial.

Authors:  Bingfeng Han; Wu Liu; Juan Du; Hanyu Liu; Tianshuo Zhao; Shubo Yang; Shuai Wang; Sihui Zhang; Bei Liu; Yaqiong Liu; Fuqiang Cui
Journal:  Vaccines (Basel)       Date:  2021-11-29

7.  Incidence trend and disease burden of seven vaccine-preventable diseases in Shandong province, China, 2013-2017: Findings from a population-based observational study.

Authors:  Zhen-Wei Li; Chao-Nan Yin; Hai-Tao Wang; Wan-Yu Du; Wen-Jing Wang; Fu-Zhong Xue; Lin Zhao; Wu-Chun Cao
Journal:  Vaccine X       Date:  2022-02-05

8.  Spatio-Temporal Epidemiology of Viral Hepatitis in China (2003-2015): Implications for Prevention and Control Policies.

Authors:  Bin Zhu; Jinlin Liu; Yang Fu; Bo Zhang; Ying Mao
Journal:  Int J Environ Res Public Health       Date:  2018-04-02       Impact factor: 3.390

9.  Study on Status and Willingness towards Hepatitis B Vaccination among Migrant Workers in Chongqing, China: A Cross-Sectional Study.

Authors:  Hui Xiang; Xiaojun Tang; Meng Xiao; Lin Gan; Kun Chu; Shan Li; Yu Tian; Xun Lei
Journal:  Int J Environ Res Public Health       Date:  2019-10-22       Impact factor: 3.390

10.  Epidemiological characteristics and trends of notifiable infectious diseases in China from 1986 to 2016.

Authors:  Yi Jiang; Xiangfeng Dou; Chenqi Yan; Li Wan; Haican Liu; Machao Li; Ruibai Wang; Guilian Li; Lili Zhao; Zhiguang Liu; Xiuqin Zhao; Kanglin Wan
Journal:  J Glob Health       Date:  2020-12       Impact factor: 4.413
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.